Skip to main content
. 2011 Nov 18;9(11):2397–2408. doi: 10.3390/md9112397

Figure 3.

Figure 3

Neoamphimedine inhibits Metnase-enhanced cell proliferation. (a) Untreated HEK293 and HEK293-Metnase cell proliferation after 72 hours relative to day 0; (b) Relative growth of etoposide treated HEK293 (IC50 = 0.6 μM) and HEK293-Metnase (IC50 = 0.4 μM) cells to untreated cells after 72 h; (c) Relative growth over the concentration range 1–4 μM emphasizing resistance to etoposide in HEK293-Metnase cells; (d) Relative growth of neoamphimedine treated HEK293 (IC50 = 0.8 μM) and HEK293-Metnase (IC50 = 0.5 μM) cells to untreated cells after 72 h; (e) Relative growth over the concentration range 1–4 μM emphasizing sensitivity to neoamphimedine in HEK293-Metnase cells. Statistical significance was determined using the unpaired, two-tailed t-test analysis, where (*) denotes P ≤ 0.05.